We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$15.6B
$294M 11.22%
4,791,589
+1,214,000
+34% +$64.1M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$270M 10.31%
17,888,597
+591,925
+3% +$7.83M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$32.1B
$210M 8.03%
1,788,802
-43,959
-2% -$3.75M
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
$132M 5.06%
4,264,066
+330,139
+8% +$9.28M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$129M 4.91%
3,670,357
+222,055
+6% +$3.01M
PBYI icon
6
Puma Biotechnology
PBYI
$481M
$111M 4.23%
923,820
+190,500
+26% +$17.7M
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
$75M 2.87%
2,157,011
– –
TVTX icon
8
Travere Therapeutics
TVTX
$6.32B
$66.9M 2.55%
2,686,204
+13,895
+0.5% +$306K
AVXS
9
DELISTED
AveXis, Inc. Common Stock
AVXS
$64.9M 2.48%
671,181
+400,000
+148% +$36.1M
CORI
10
DELISTED
Corium International, Inc.
CORI
$64.8M 2.48%
5,847,133
– –
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$60.3M 2.3%
1,616,259
+905,000
+127% +$31.4M
TSRO
12
DELISTED
TESARO, Inc.
TSRO
$50.2M 1.92%
388,651
+29,100
+8% +$3.61M
RGNX icon
13
Regenxbio
RGNX
$588M
$47.5M 1.81%
1,441,186
+70,000
+5% +$1.58M
DOVA
14
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$42.6M 1.63%
1,754,015
+47,516
+3% +$1.13M
IOVA icon
15
Iovance Biotherapeutics
IOVA
$3.82B
$36.6M 1.4%
4,726,114
+363,000
+8% +$2.3M
NXTM
16
DELISTED
NxStage Medical Inc.
NXTM
$34.9M 1.33%
1,264,523
-291,000
-19% -$7.76M
ANAB icon
17
AnaptysBio
ANAB
$1.73B
$34.3M 1.31%
982,269
+30,000
+3% +$809K
AKBA icon
18
Akebia Therapeutics
AKBA
$266M
$32.1M 1.22%
1,630,000
+530,000
+48% +$8.15M
XNCR icon
19
Xencor
XNCR
$2.18B
$29.6M 1.13%
1,293,095
– –
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$29.6M 1.13%
424,661
-20,000
-4% -$1.07M
ISRG icon
21
Intuitive Surgical
ISRG
$131B
$26.4M 1.01%
226,755
+40,500
+22% +$4.41M
VBIV
22
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$25.3M 0.97%
218,861
– –
CTMX icon
23
CytomX Therapeutics
CTMX
$734M
$25.3M 0.97%
1,390,381
– –
DBVT
24
DBV Technologies
DBVT
$941M
$24.5M 0.93%
57,642
-1,535
-3% -$658K
HUM icon
25
Humana
HUM
$46.8B
$24.4M 0.93%
100,000
+21,907
+28% +$5.37M
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.